2021 Volume 51 Issue 2 Pages 73-77
Valvular heart disease (VHD) is one of the important etiologies for heart failure, in that severe dysfunction of aortic and mitral valves causes worse clinical outcomes. While the guidelines on the management of VHD have been updated in early 2020 in Japan, the environment surrounding this field has been rapidly evolving. Recently, catheter-based interventional technologies for VHD have been developed. Transcatheter aortic valve implantation (TAVI) has become a preferred interventional strategy for treatment of elderly or high-risk surgical patients with severe aortic stenosis. Moreover, transcatheter mitral valve edge-to-edge repair with MitraClip offers an alternative to open surgical repair or replacement in patients with severe mitral regurgitation at increased risk for surgery. The aim of this mini-review is to briefly mention the recent updates of the guidelines on VHD in Japan, and current issues and future prospects of TAVI and MitraClip.
